Browse

A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder

DC Field Value Language
dc.contributor.authorKim, Chang Yoon-
dc.contributor.authorChung, Seockhoon-
dc.contributor.authorLee, Joon-Noh-
dc.contributor.authorKwon, Jun Soo-
dc.contributor.authorKim, Chul Eung-
dc.contributor.authorJeon, Yang-Whan-
dc.contributor.authorJun, Tae-Youn-
dc.contributor.authorJung, Hee-Yeon-
dc.contributor.authorLee, Min-Soo-
dc.contributor.authorJeong, Bumseok-
dc.contributor.authorKim, Do Hoon-
dc.date.accessioned2012-07-05T04:48:20Z-
dc.date.available2012-07-05T04:48:20Z-
dc.date.issued2009-07-
dc.identifier.citationINTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY; Vol.24 4; 181-188ko_KR
dc.identifier.issn0268-1315-
dc.identifier.urihttps://hdl.handle.net/10371/78590-
dc.description.abstractThe objectives of this 12-week multicenter open-label switching study were to evaluate the overall clinical efficacy, safety, and tolerability of aripiprazole in stable patients with schizophrenia or schizoaffective disorder, and to assess, in a naturalistic setting, whether such patients experience symptom worsening when switched from D(2) receptor antagonists to aripiprazole (a D(2) receptor partial agonist). Patients with schizophrenia or schizoaffective disorder in a symptomatically stable state were randomized to aripiprazole or standard-of-care antipsychotics. The Clinical Global Impression (CGI), Positive and Negative Syndrome Scale, and Investigator`s Assessment Questionnaire were used monthly. The Udvalg for Kliniske Undersogelser side-effect rating scale scores and treatment emergent adverse events were recorded to assess the safety and tolerability of switching to aripiprazole from other antipsychotics. A total of 292 patients were randomly assigned to receive aripiprazole (N=245) or non-aripiprazole antipsychotics (N=47). Mean CGI-Improvement score at 12 weeks was 3.56 +/- 1.29 (95% confidence interval: 3.39-3.73) in the aripiprazole group, indicating that aripiprazole was effective in treating schizophrenic patients. Aripiprazole treatment resulted in improvement from baseline on all efficacy outcome measures, including Positive and Negative Syndrome Scale total, positive, negative, and general subscale, and CGI-Severity scores. In addition, after aripiprazole treatment, the remission rate was increased from 43.9% at baseline to 51.7% at 12 weeks. The proportion of patients with symptom worsening at 12 weeks was low (12.4%). Both Investigator`s Assessment Questionnaire and Udvalg for Kliniske Undersogelser scores showed that there were fewer prolactin-related adverse events in the aripiprazole group than in the standard-of-care antipsychotics group (P<0.05). There were no significant between-group differences in time to failure to maintain remission and time to dropout. In the naturalistic setting, symptomatically stable outpatients with schizophrenia who were switched to aripiprazole showed clinically meaningful treatment benefits. The majority of patients was successfully switched from other antipsychotics without serious symptom exacerbation or adverse events over a course of 12 weeks. Int Clin Psychopharmacol 24:181-188 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.ko_KR
dc.description.sponsorshipThis study was supported by the Otsuka Pharmaceutical
Co. Ltd.
ko_KR
dc.language.isoenko_KR
dc.publisherLIPPINCOTT WILLIAMS & WILKINSko_KR
dc.subjectaripiprazoleko_KR
dc.subjectefficacyko_KR
dc.subjectswitchingko_KR
dc.subjectschizophreniako_KR
dc.subjectsafetyko_KR
dc.titleA 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorderko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김창윤-
dc.contributor.AlternativeAuthor정석훈-
dc.contributor.AlternativeAuthor이준노-
dc.contributor.AlternativeAuthor권준수-
dc.contributor.AlternativeAuthor김도훈-
dc.contributor.AlternativeAuthor이철응-
dc.contributor.AlternativeAuthor정범석-
dc.contributor.AlternativeAuthor전양환-
dc.contributor.AlternativeAuthor이민수-
dc.contributor.AlternativeAuthor전태윤-
dc.contributor.AlternativeAuthor정희연-
dc.identifier.doi10.1097/YIC.0b013e32832c25d7-
dc.citation.journaltitleINTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY-
dc.description.citedreferenceTandon R, 2008, SCHIZOPHR RES, V100, P20, DOI 10.1016/j.schres.2007.11.033-
dc.description.citedreferenceWolf J, 2007, CURR MED RES OPIN, V23, P2313, DOI 10.1185/030079907X225448-
dc.description.citedreferenceKim SH, 2007, J CLIN PSYCHOPHARM, V27, P365, DOI 10.1097/JCP.0b013e3180a9076c-
dc.description.citedreferenceHenderson DC, 2007, J CLIN PSYCHIAT, V68, P18-
dc.description.citedreferenceTandon R, 2006, SCHIZOPHR RES, V84, P77, DOI 10.1016/j.schres.2005.12.857-
dc.description.citedreferencevan Os J, 2006, ACTA PSYCHIAT SCAND, V113, P91, DOI 10.1111/j.1600-0447.2005.00659.x-
dc.description.citedreferenceLieberman JA, 2005, NEW ENGL J MED, V353, P1209-
dc.description.citedreferenceTandon R, 2005, PSYCHIAT RES, V136, P211, DOI 10.1016/j.psychres.2005.05.006-
dc.description.citedreferenceAndreasen NC, 2005, AM J PSYCHIAT, V162, P441-
dc.description.citedreferenceCHUNG S, 2005, KOREAN J PSYCHOPHARM, V16, P109-
dc.description.citedreferenceMcQuade RD, 2004, J CLIN PSYCHIAT, V65, P47-
dc.description.citedreferenceLieberman JA, 2004, CNS DRUGS, V18, P251-
dc.description.citedreferenceKasper S, 2003, INT J NEUROPSYCHOPH, V6, P325, DOI 10.1017/S1461145703003651-
dc.description.citedreferencePigott TA, 2003, J CLIN PSYCHIAT, V64, P1048-
dc.description.citedreferencePotkin SG, 2003, ARCH GEN PSYCHIAT, V60, P681-
dc.description.citedreferenceMarder SR, 2003, SCHIZOPHR RES, V61, P123, DOI 10.1016/S0920-9964(03)00050-1-
dc.description.citedreferenceCasey DE, 2003, PSYCHOPHARMACOLOGY, V166, P391, DOI 10.1007/s00213-002-1344-3-
dc.description.citedreferenceGanguli R, 2002, AM J HEALTH-SYST PH, V59, pS22-
dc.description.citedreferenceKane JM, 2002, J CLIN PSYCHIAT, V63, P763-
dc.description.citedreferenceMaguire GA, 2002, J CLIN PSYCHIAT, V63, P56-
dc.description.citedreferenceMcIntyre RS, 2001, J CLIN PSYCHIAT, V62, P23-
dc.description.citedreferenceWeiden PJ, 1997, J CLIN PSYCHIAT, V58, P63-
dc.description.citedreferenceLINGJAERDE O, 1987, ACTA PSYCHIATR SCA S, V334, P1-
dc.description.citedreferenceGARDOS G, 1974, J NERV MENT DIS, V159, P343-
dc.description.tc3-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Psychiatry (정신과학전공)Journal Papers (저널논문_정신과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse